Long Covid affects millions: Scientists begin trial for potential breakthrough treatment
Long Covid
remains a major concern for millions worldwide. After an infection caused by the SARS-CoV-2 virus, many individuals continue to experience a wide range of symptoms that disrupt their daily lives. These persistent issues, which can include fatigue, brain fog, and breathing difficulties, are collectively known as Long Covid. The condition is still not fully understood, and it presents with different symptoms. As researchers search for effective treatments, a new clinical trial has emerged, offering hope for those affected.
Scientists launch clinical trial for
Sipavibart
A team of researchers from
Nova Southeastern University
(NSU) in the United States, in partnership with the
Schmidt Initiative for Long Covid
(SILC), has launched a clinical trial to evaluate the effectiveness of sipavibart. This long-acting monoclonal antibody, developed by AstraZeneca, has already been approved in countries like Japan and the EU for preventing COVID-19 before exposure. However, this trial is the first time it will be tested for its ability to ease
Long Covid symptoms
.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Google Brain Co-Founder Andrew Ng, Recommends: Read These 5 Books And Turn Your Life Around
Blinkist: Andrew Ng's Reading List
Undo
The clinical trial has already enrolled 100 patients and aims to collect data over the next few years to see if sipavibart can help reduce the many symptoms of Long Covid. Approved by the Food and Drug Administration (FDA) earlier this year, researchers are hopeful this treatment could offer significant relief to those affected by the condition.
A complex and confusing condition
Long Covid is a condition that continues to puzzle both patients and medical professionals. With over 200 reported symptoms, the effects of the illness can vary greatly from person to person. While some people experience only mild symptoms that come and go, others face severe, long-lasting challenges that can severely impact their quality of life.
'Like many multi-symptom, post-viral conditions, Long Covid is incredibly complicated and thus little understood,' explained Dr. Nancy Klimas, director of the Institute for Neuro-Immune Medicine at NSU. 'Finding a treatment will be life-changing for patients suffering from the myriad symptoms of Long Covid.'
The complexity of Long Covid has made it hard to find a treatment that works for everyone. This is why the trial of sipavibart is considered an important step, as it may offer a much-needed solution for those affected.
Sipavibart: A promising treatment option
Sipavibart's potential as a treatment for Long Covid is still being tested, but there is increasing hope. The monoclonal antibody works by targeting and neutralizing the virus, and researchers believe it could help patients recover more quickly and with fewer long-term health problems. While sipavibart is already approved for Covid-19 prevention, this trial explores its new use to treat the ongoing symptoms of Long Covid.
Dr. John Redd, CEO of SILC, pointed out the scale of the problem: 'Long Covid affects at least 65 million people worldwide, and with more than 200 symptoms, the health impacts of the disease can be debilitating. This trial represents our overall commitment to addressing the most pressing health challenges of our time.'
A collaborative effort
This trial is more than just a study; it's a team effort to address one of the biggest health issues today. With millions suffering from a wide range of symptoms, finding a treatment for Long Covid is critical. Researchers are hopeful that sipavibart could help manage these symptoms and give patients a chance to get back to normal life.
'We're leveraging our research expertise to potentially transform treatment options for millions suffering from Long Covid, advance knowledge, and improve patient outcomes through innovative clinical research,' said Dr. Ken Dawson-Scully, NSU's senior vice president for research and associate provost.
Masterclass for Students. Upskill Young Ones Today!– Join Now
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
43 minutes ago
- Time of India
GRH sets up 50-bed Covid-19 ward as precaution
Madurai: Amid a recent uptick in Covid-19 cases across Tamil Nadu, Government Rajaji Hospital (GRH) in Madurai has set up a dedicated 50-bed isolation ward as a precautionary step. Tired of too many ads? go ad free now While no active cases have been reported in the city, health officials are urging the public to wear masks and maintain hand hygiene in crowded areas. The isolation facility includes 30 beds for adults and 20 for children. GRH dean Dr L Arul Sundaresh Kumar said the hospital is fully prepared to manage any potential Covid-19 cases, following directions from the state health department. "We have ample supplies of medicines and oxygen. OPD staff have been instructed to wear masks and follow hygiene protocols. Covid testing will be conducted only if deemed necessary," he said, adding that fever cases are being closely monitored. Health officials clarified there has been no spike in Influenza-Like Illness (ILI) or Severe Acute Respiratory Infection (SARI) cases. "There were a few fever cases after the rains, but no clusters or surges have been identified. People are advised to avoid self-medication and seek medical advice for persistent symptoms," an official said. Surveillance has also been tightened at Madurai airport. Passengers arriving from abroad with fever or cough are being screened and isolated if needed. A 16-member monitoring team has been deployed for airport vigilance. MSID:: 121652081 413 |
Time of India
an hour ago
- Time of India
Pollutants order changes post Covid pandemic: Cooking, industry emissions on PM2.5 rogue list
1 2 3 4 Kolkata: On the occasion of World Environment Day, the West Bengal Pollution Control Board (WBPCB) released a comprehensive report revealing how Kolkata's air pollution sources had significantly shifted in the years following Covid-19 pandemic. The analysis, drawing on two landmark studies — NEERI's pre-pandemic source apportionment study (2019) and TERI's recent post-pandemic study (2025) — shows a perceptible change in sectoral contribution to two key pollutants: PM10 and PM2.5. Significantly, only these two pollutants breach the national ambient air quality standard (NAAQS). Earlier, releasing the report, Bengal environment minister Chandrima Bhattacharya, WBPCB chairman Kalyan Rudra, additional chief secretary of the environment department Roshni Sen, former VC of Bengal Engineering and Science University (BESU) Ajay Roy, and WBPCB member secretary J P Meena emphasised how plastic pollution plays havoc with our lives and biodiversity. WBPCB chairman Kalyan Rudra declared an award for students for collecting and responsible disposal of plastic wastes through its network of 5,000-plus schools in Bengal. According to the findings, coarse particulate matter (PM10) in the city saw a decrease in dust-related emissions, from a dominant 57.3% in 2019 to 43% in 2025, suggesting possible improvements in street cleaning and construction regulation. However, this was offset by rising contributions from household cooking (from 13.3% to 18%), industry (5.9% to 12%), and vehicular tailpipe emissions (8% to 13%). Notably, refuse burning and secondary sources, which were negligible in 2019, emerged as more prominent contributors in 2025. Fine particulate matter (PM2.5), which poses graver health risks due to its ability to penetrate deep into the lungs, now sees an increased contribution from industrial emissions (7% to 21%) and cooking (27.9% to 29%). Dust emissions halved (from 24.7% to 12%), while secondary aerosols — a complex mixture formed through chemical reactions involving vehicle, industrial, and power plant emissions — came into sharp focus, now accounting for 13% of PM2.5. This rise suggests a growing influence of chemical pollutants in the city's atmosphere. The report also notes that while policies such as the introduction of BSVI vehicles and the uptake of electric mobility helped reduce PM2.5 from tailpipes (23.5% to 20%), older vehicle fleets continue to be significant emitters of PM10.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
India's active case tally nears 5K as country reports 7 deaths in 24 hours
India recorded 4,866 active Covid-19 cases as of June 5, with seven deaths reported in the last 24 hours, according to the latest data from the Ministry of Health and Family Welfare. Among states, Kerala had the highest caseload at 1,487, followed by Delhi and West Bengal with 562 and 538 cases respectively. Maharashtra (526), Gujarat (508) and Karnataka (436) are the other states to cross the 400 active cases mark. These six states currently account for 83 per cent of India's total active infections. Five of the seven fatalities were senior citizens over the age of 60. The others included a 42-year-old man from Delhi and a five-month-old male child from Karnataka, both with multiple health issues alongside a positive Covid test result. This rise in cases comes even as the Centre is conducting mock drills in government hospitals to check preparedness for Covid-19. Official sources say hospitalisations have not increased, as most cases are mild and treated under home care. States have also been instructed to ensure availability of oxygen, isolation beds, ventilators and essential medicines, sources said. A mock drill assessing oxygen supply systems such as PSA plants, LMO tanks and MGPS lines was conducted on June 2.
